Flawless Pharma to Invest USD 100 Million in Buyout of Assets & Patents in Hong Kong and China

Flawless Pharma Private Limited, a research-based integrated pharmaceutical company involved in niche API manufacturing and marketing of pharmaceutical ingredient supplier for leading formulators with services such as APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations, has announced today that the company will invest approximately USD 100 million. The investment would go towards the acquisition of patent assets in Hong Kong and China.

According to industry experts, Flawless Pharma's proposal to invest around USD 100 million in the acquisition of assets and patents will establish a precedent for others to follow. Flawless Pharma Pvt Limited's foreign investments in two important sites will consolidate annual income and bring up a myriad of prospects in the challenging R & D areas of NCE & NDDS. Dr. Sujeet Kumar Singh, Managing Director of the unlisted pharma company Flawless Pharma Pvt Limited, announced the USD 100 million investment, saying, "The Board of Directors & Management has endorsed the proposal to invest USD 100 million in buyout of assets and patents and has successfully raised funds from Investors including Capital trade Napian Finance amongst other investors for long term investments."

The investment would go towards the acquisition of patent assets in Hong Kong, China. This investment will provide vital access to Hong Kong, China, and Slovakia, which is located in Central Europe and has enormous market potential and greater market access. This investment is consistent with our long-term goal of being the dominant player in Hong Kong China. According to industry sources in India, the company has raised financing from NBFCs Napian and Capital, among others, and obtained requisite investment licences. The investment of 100 Million US Dollars in Hong Kong Company have patents assets in china and. Flawless Pharma Private Limited has been rated A Category by USA based rating company Owens Online Inc has a turnover of 600 plus Cores and Net worth of 400 crores, Gaurav Singh , Executive Director of Flawless Pharma Pvt Limited said "this will be landmark investments of Flawless Pharma Pvt Limited in Hong Kong & Slovakia chosen carefully after due diligence & market conditions. Patent and public procurement systems can help promote productivity-led growth by improving technology diffusion and supporting innovative solutions. Patents and innovation public procurement can be effective instruments to help countries boost innovation and make a resilient and inclusive recovery without excessive fiscal burdens.

Asian economy patent filings accounted for more than 66% of the world's total in 2020. Flawless Pharma Pvt Ltd has recently added yet another feather in its cap of achievements by begging the the prestigious Emerging Pharmaceutical Company of The Year 2023 on 28th July 2023 at Hotel Radisson in Mumbai, india. The Award Trophy & Certificate of Excellence was awarded by renowned model, actress, psychologist & India's first Mrs World Dr. Aditi Govitrikar in a power packed event that brought together World-leading Businesses, Global thought Leaders from all fields of Industrial and Service Sectors, Business Leaders, Key Decision Makers, Members of Government Organizations and non-Govt. organizations.